PUBLISHER: The Business Research Company | PRODUCT CODE: 2160924
PUBLISHER: The Business Research Company | PRODUCT CODE: 2160924
Drug-eluting device coating services refer to specialized services that apply drug-containing or drug-releasing coatings to medical devices to facilitate the controlled and localized delivery of therapeutic agents at the intended treatment site. These services emphasize achieving consistent drug loading, coating uniformity, adhesion, stability, and controlled drug-release performance while complying with applicable quality and regulatory requirements.
The main service types of drug-eluting device coating services include drug-eluting coating application, coating formulation development, surface preparation and pretreatment, coating process development, drug loading and release optimization, coating validation and testing, analytical characterization, and regulatory and quality support. Drug-eluting coating application refers to the process of applying a drug-containing coating to the surface of a medical device to facilitate controlled drug release at the intended site of treatment. These services support various drug types, including antiproliferative drugs, anti-inflammatory drugs, antimicrobial drugs, antithrombotic drugs, and combination drugs. Drug-eluting device coating services are utilized across cardiovascular devices, orthopedic implants, neurological and peripheral vascular devices, and wound care and general surgery devices. The key end users of these services include medical device manufacturers, contract manufacturing organizations, research and development organizations, academic and research institutes, and other end users.
Tariffs are influencing the drug-eluting device coating services market by increasing the costs of imported coating materials, pharmaceutical ingredients, medical device components, and specialized processing equipment required for manufacturing drug-eluting devices. These higher expenses are increasing service costs and creating supply-chain pressures across cardiovascular devices, orthopedic implants, neurological devices, and wound care applications, particularly in regions that depend on imported medical technologies such as Asia-Pacific, Europe, and Latin America. Drug-intensive and specialized coating services are particularly exposed because they rely on globally sourced APIs, polymers, excipients, and other manufacturing inputs. However, tariffs are also encouraging regional sourcing, domestic production of coating materials, and increased investment in localized medical device manufacturing and coating capabilities, supporting long-term supply-chain resilience.
The drug-eluting device coating services market research report is one of a series of new reports from The Business Research Company that provides drug-eluting device coating services market statistics, including drug-eluting device coating services industry global market size, regional shares, competitors with a drug-eluting device coating services market share, detailed drug-eluting device coating services market segments, market trends and opportunities, and any further data you may need to thrive in the drug-eluting device coating services industry. This drug-eluting device coating services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The drug-eluting device coating services market size has grown strongly in recent years. It will grow from $1.04 billion in 2025 to $1.1 billion in 2026 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to the increasing incidence of cardiovascular diseases, growing adoption of drug-eluting medical technologies, rising demand for minimally invasive treatments, increasing utilization of coated cardiovascular implants, and growing demand for localized therapeutic drug delivery.
The drug-eluting device coating services market size is expected to see strong growth in the next few years. It will grow to $1.43 billion in 2030 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to increasing demand for advanced drug-release profiles, rising adoption of combination drug coatings, growing utilization of drug-eluting coatings in emerging medical device applications, increasing demand for personalized therapeutic delivery, expanding requirement for specialized coating development and validation services. Major trends in the forecast period include growing demand for precise control over drug loading and release, increasing adoption of uniform and durable drug-eluting coatings, rising demand for biocompatible coating materials, increasing emphasis on coating adhesion and long-term stability, expanding requirement for regulatory-compliant coating validation and testing.
The growing demand for localized drug delivery is expected to propel the growth of the drug-eluting device coating services market going forward. Localized drug delivery is a therapeutic approach that delivers drugs directly to the targeted site of a disease, improving treatment efficacy while minimizing systemic side effects. The demand for localized drug delivery is increasing due to the rising prevalence of chronic diseases that require targeted and sustained therapeutic interventions. Drug-eluting device coating services support localized drug delivery by applying specialized coatings that enable medical devices to release therapeutic agents in a controlled manner directly at the treatment site, enhancing clinical performance and patient outcomes. For instance, in November 2024, according to the Spanish Society of Cardiology, a Spain-based professional medical society, percutaneous coronary interventions performed exclusively with drug-coated balloons increased from 2,891 procedures in 2022 to 3,852 procedures in 2023, representing a 33.2% year-on-year increase, while the cumulative increase from 2021 to 2023 reached 92%, reflecting the growing adoption of localized drug-delivery technologies in coronary interventions. Therefore, the growing demand for localized drug delivery is driving the growth of the drug-eluting device coating services market.
Leading companies operating in the drug-eluting device coating services market are focusing on developing advanced services, such as next-generation coating services, to improve patient safety, enhance procedural efficacy, and reduce complications. Next-generation coating services refer to advanced manufacturing processes that apply therapeutic agents onto medical devices with exceptional uniformity, aiming to optimize drug transfer efficiency and minimize particulate generation. For example, in June 2023, Surmodics Inc., a US-based medical device technology company, announced FDA approval for its SurVeil drug-coated balloon (DCB), which features its proprietary drug-excipient formulation and an innovative manufacturing process. This next-generation DCB is designed to deliver a substantially lower drug dose (2.0 µg/mm2) with more uniform coating distribution. It is intended for the treatment of peripheral artery disease and has demonstrated noninferior safety and effectiveness at 24 months compared to a market-leading high-dose DCB, which may reduce the risk of downstream particulates and emboli while improving patient outcomes and potentially lowering healthcare costs associated with repeat revascularization procedures.
In February 2025, Integer Holdings Corporation, a US-based medical device contract development and manufacturing company, acquired Precision Coating Inc. for an undisclosed amount. Through this acquisition, Integer aimed to enhance its medical device coating and surface-modification capabilities while broadening its portfolio of advanced coating solutions. Precision Coating Inc. is a US-based specialized medical device coating company that provides coating and surface-treatment technologies for patient-critical medical devices.
Major companies operating in the drug-eluting device coating services market are Medtronic plc, Freudenberg Medical LLC, Integer Holdings Corporation, Viant Medical LLC, Harland Medical Systems Inc, Precision Coating Company LLC, Specialty Coating Systems Inc, Hydromer Inc, Covalon Technologies Ltd, Nordson Medical Corporation, Secant Group LLC, Sono-Tek Corporation, AST Products Inc, Formacoat LLC, Advanced Deposition & Coating Technologies Inc, Medibrane Ltd, Surgical Coatings LLC, Applied Medical Coatings LLC, Stenocoat Sp z o o, CD Bioparticles
North America was the dominating region in the drug-eluting device coating services market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the drug-eluting device coating services market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the drug-eluting device coating services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The drug-eluting device coating services market includes revenues earned by entities through drug-polymer compatibility assessment, polymer selection and optimization, drug stability and degradation assessment, coating adhesion enhancement and coating thickness optimization. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Drug-Eluting Device Coating Services Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses drug-eluting device coating services market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for drug-eluting device coating services? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The drug-eluting device coating services market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope are limited to 20% of content and consultant support time is limited to 8 hours.